| Literature DB >> 3667165 |
D A Amato1, H Bruckner, D Guerry, A Ash, G Falkson, E C Borden, R H Creech, E D Savlov, T J Cunningham.
Abstract
In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma. The response rates were 6% (3/50) for AHC, 9% (3/34) for DBD, and 14% (7/49) for methyl-CCNU. Median survival times were 4, 5, and 6 months, respectively. Neither regimen appears to offer any advantage over methyl-CCNU as front-line therapy for patients with disseminated melanoma.Entities:
Mesh：
Substances：
Year: 1987 PMID： 3667165 DOI： 10.1007/bf00175301
Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850